B. Riley Lowers Sensus Healthcare (NASDAQ:SRTS) to Neutral

Share on StockTwits

B. Riley lowered shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a report issued on Thursday morning, Briefing.com Automated Import reports. B. Riley currently has $5.50 target price on the stock, down from their prior target price of $14.00.

SRTS has been the topic of several other research reports. HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Sensus Healthcare in a report on Thursday. TheStreet upgraded Sensus Healthcare from a d+ rating to a c- rating in a report on Monday, August 26th. Maxim Group set a $11.00 price objective on Sensus Healthcare and gave the stock a buy rating in a report on Friday, August 9th. Finally, ValuEngine downgraded Sensus Healthcare from a buy rating to a hold rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $8.30.

Shares of Sensus Healthcare stock traded down $0.21 during trading hours on Thursday, reaching $3.80. The company had a trading volume of 73,900 shares, compared to its average volume of 31,014. The business has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $5.72. Sensus Healthcare has a one year low of $3.71 and a one year high of $9.23. The firm has a market cap of $93.54 million, a PE ratio of -27.14 and a beta of -0.41.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $7.77 million. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. As a group, equities research analysts predict that Sensus Healthcare will post -0.12 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN purchased a new position in shares of Sensus Healthcare in the second quarter worth about $30,000. Susquehanna International Group LLP increased its holdings in shares of Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares during the period. Essex Investment Management Co. LLC purchased a new position in shares of Sensus Healthcare in the third quarter worth about $540,000. BlackRock Inc. increased its holdings in Sensus Healthcare by 40.7% during the 2nd quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock valued at $574,000 after purchasing an additional 29,990 shares during the period. Finally, Heartland Advisors Inc. increased its holdings in Sensus Healthcare by 150.0% during the 2nd quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock valued at $2,078,000 after purchasing an additional 225,000 shares during the period. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

B. Riley Lowers Sensus Healthcare  to Neutral
B. Riley Lowers Sensus Healthcare to Neutral
Encore Capital Group  Earns “Buy” Rating from Northland Securities
Encore Capital Group Earns “Buy” Rating from Northland Securities
BAE Systems  Receives “Buy” Rating from Deutsche Bank
BAE Systems Receives “Buy” Rating from Deutsche Bank
$94.14 Million in Sales Expected for Tenable Holdings Inc  This Quarter
$94.14 Million in Sales Expected for Tenable Holdings Inc This Quarter
Innova  Achieves Market Capitalization of $31,166.00
Innova Achieves Market Capitalization of $31,166.00
LNX Protocol Price Up 94.5% Over Last Week
LNX Protocol Price Up 94.5% Over Last Week


 
© 2006-2019 Zolmax.